News

GSK fuels French fund with €18m
Enlarge image

FundingFranceUK

GSK fuels French fund with €18m

24.06.2013 - British GlaxoSmithKline is participating in the new Kurma Biofund II in France. €17.5m of the €44m raised so far comes from GSK.

In a bid to identify promising new targets and drugs, British Pharma GlaxoSmithKline gains a foothold in a rare diseases venture fund. GSK said last week it will invest €17.5m in the Kurma Biofund II. It is the first venture capital fund dedicated to financing innovation in the rare diseases field through working with a network of European research institutes. Lead investor is the French firm Kurma Life Sciences Partners, with other backers including CDC Enterprises, Idinvest Partners and New Enterprise Associates. So far €44m has been raised. In April, GSK took a another bigger step when it decided to team up with Avalon Ventures in a deal worth up to €375m to fund ten drug discovery start-ups over the next three years (also see EuroBiotechNews Special May/2013).

Kurma Biofund I, valued at €51m, is still managed by Paris-based Kurma Life Sciences Partners. Like Biofund II this fund seeks the establishment of a new economic model for the financing of innovation – based on strategic partnerships with highly reputable biotechnology and medical research centers in France and the rest of Europe. Whereas Biofund II is targeted to rare diseases, Biofund I is largely concerned with life sciences and the health sector in general. Biofund I included enterprises ABM Medical, AM Pharma, Blink, Indigix, Key Neurosciences, Meiogenix, Pathoquest, Safe Orthopaedics, Umecrine and Zealand Pharma. Zealand recently made the news with its Sanofi-co-development. Since May Lyxumia has a European marketing authorisation as a diabetes therapy.

UPDATE: Later that day the EMA published a draft about the planned changes ("Publication and Acess to Clinical-Trial Data").

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/gsk-fuels-french-fund-with-eur18m.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR32.3%
  • ADDEX3.44 CHF7.8%
  • HBM86.00 CHF4.4%

FLOP

  • PAION2.19 EUR-32.8%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-25.0%

TOP

  • SANTHERA82.00 CHF2184.1%
  • CO.DON2.82 EUR200.0%
  • PAION2.19 EUR157.6%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 22.10.2014